Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554797 | 0.84 | ABL1 (0.33) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL3558571 | 0.84 | IGF1R (0.33) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL2200361 | 0.84 | KDM4E (0.42) | KDM4EGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2198656 | 0.83 | BRD4 (0.35) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL2200414 | 0.83 | BRD4 (0.38) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL3552402 | 0.83 | GABRA1 (0.38) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL2198235 | 0.82 | KDM4E (0.32) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL3557071 | 0.81 | MKNK1 (0.36) | KDM4EIGF1RGABRA1GABRG2GABRB3 | |
| SCHEMBL3552658 | 0.81 | GABRA1 (0.40) | IGF1RGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3553100 | 0.81 | KDM4E (0.39) | KDM4EIGF1RCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | KDM4E 489/4885NR1H2 1537/4885NR1H3 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.